Zentalis Pharmaceuticals Inc
ZNTL
$11.06
Closing
▼-6.67%
1D
▼-27.49%
YTD
Market cap
$784.82M
52 week high
$31.46
52 week low
$9.56
Volume
222,460
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$784.82M
Analysts' Rating
BUY
Price Target (Mean)
34.40
Total Analysts
11
P/E
Operating Margin
0.00%
Beta
1.82
Revenue Growth (Annual)
-
52 week high
$31.46
52 week low
$9.56
Div. Yield
%
EPS Annual Growth
17.72
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Zentalis Pharmaceuticals Inc is a United States-based company. The Company develops small molecule therapeutics with differentiated product profiles for a broad range of cancers. It is focused on pipeline of oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a B-cell lymphoma 2 (BCL-2) inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.
